

ARRAY BIOPHARMA INC  
Form 4  
March 04, 2015

# FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION  
Washington, D.C. 20549

OMB APPROVAL

OMB Number: 3235-0287  
Expires: January 31, 2005  
Estimated average burden hours per response... 0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

## STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940

(Print or Type Responses)

1. Name and Address of Reporting Person \*  
LEFKOFF KYLE

(Last) (First) (Middle)

C/O ARRAY BIOPHARMA  
INC., 3200 WALNUT STREET

(Street)

BOULDER, CO 80301

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol  
ARRAY BIOPHARMA INC  
[ARRY]

3. Date of Earliest Transaction  
(Month/Day/Year)  
03/03/2015

4. If Amendment, Date Original Filed(Month/Day/Year)

5. Relationship of Reporting Person(s) to Issuer

(Check all applicable)

Director  10% Owner  
 Officer (give title below)  Other (specify below)

6. Individual or Joint/Group Filing(Check Applicable Line)  
 Form filed by One Reporting Person  
 Form filed by More than One Reporting Person

### Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

| 1. Title of Security (Instr. 3) | 2. Transaction Date (Month/Day/Year) | 2A. Deemed Execution Date, if any (Month/Day/Year) | 3. Transaction Code (Instr. 8) | 4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) |   |        | 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) | 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) | 7. Nature of Indirect Beneficial Ownership (Instr. 4) |            |       |
|---------------------------------|--------------------------------------|--|--------------------------------|---|---|--------|---|--|---|------------|-------|
|                                 |                                      |  |                                | Code  | V | Amount |   |  |   | (A) or (D) | Price |
| Common Stock                    | 03/03/2015                           |  | M                              |   |   | 15,000 | A   | \$ 3.37  | 18,585  | D          |       |
| Common Stock                    | 03/03/2015                           |  | M                              |   |   | 15,000 | A   | \$ 1.74  | 33,585  | D          |       |
| Common Stock                    | 03/03/2015                           |  | M                              |   |   | 20,000 | A   | \$ 3.51  | 53,585  | D          |       |
| Common Stock                    | 03/03/2015                           |  | M                              |   |   | 20,000 | A   | \$ 2.46  | 73,585  | D          |       |
| Common Stock                    | 03/03/2015                           |  | S                              |   |   | 70,000 | D   | \$ 8.001   | 3,585   | D          |       |

Edgar Filing: ARRAY BIOPHARMA INC - Form 4

(1)

|                 |        |   |                        |
|-----------------|--------|---|------------------------|
| Common<br>Stock | 45,000 | I | See<br>footnote<br>(2) |
|-----------------|--------|---|------------------------|

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

**Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.**

SEC 1474  
(9-02)

**Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned**  
(e.g., puts, calls, warrants, options, convertible securities)

| 1. Title of Derivative Security (Instr. 3) | 2. Conversion or Exercise Price of Derivative Security | 3. Transaction Date (Month/Day/Year) | 3A. Deemed Execution Date, if any (Month/Day/Year) | 4. Transaction Code (Instr. 8) | 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5) | 6. Date Exercisable and Expiration Date (Month/Day/Year) | 7. Title and Amount of Underlying Securities (Instr. 3 and 4) |              |                            |
|--|--|--------------------------------------|--|--------------------------------|---|--|---|--------------|----------------------------|
|  |  |                                      |  | Code                           | V (A) (D)   | Date Exercisable   | Expiration Date   | Title        | Amount or Number of Shares |
| Stock Option                               | \$ 3.37  | 03/03/2015                           |  | M                              | 15,000  | (3)  | 12/08/2018  | Common Stock | 15,000                     |
| Stock Option                               | \$ 1.74  | 03/03/2015                           |  | M                              | 15,000  | (4)  | 10/29/2019  | Common Stock | 15,000                     |
| Stock Option                               | \$ 3.51  | 03/03/2015                           |  | M                              | 20,000  | (5)  | 11/04/2020  | Common Stock | 20,000                     |
| Stock Option                               | \$ 2.46  | 03/03/2015                           |  | M                              | 20,000  | 10/26/2012   | 10/26/2022  | Common Stock | 20,000                     |

## Reporting Owners

| Reporting Owner Name / Address  | Relationships |           |         |       |
|---|---------------|-----------|---------|-------|
|   | Director      | 10% Owner | Officer | Other |
| LEFKOFF KYLE<br>C/O ARRAY BIOPHARMA INC.<br>3200 WALNUT STREET<br>BOULDER, CO 80301 |               | X         |         |       |

## Signatures

John Moore, attorney-in-fact for Reporting  
Person

03/04/2015

\_\_Signature of Reporting Person

Date

## Explanation of Responses:

- \* If the form is filed by more than one reporting person, *see* Instruction 4(b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations. *See* 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- (1) The price reflects the weighted average selling price for the 70,000 shares which were sold in the range of \$8.00 to \$8.01. Full information about the number of shares sold at each price is available upon request.
- (2) Comprised of 30,000 shares of common stock in trust for the benefit of Mr. Lefkoff's minor children and 15,000 shares of common stock held by BV Partners III Profit Sharing account for the benefit of Mr. Lefkoff.
- (3) The option vested in 3 equal annual installments beginning on November 1, 2009.
- (4) The option vested in 3 equal annual installments beginning on November 1, 2010.
- (5) The option vested in 3 equal annual installments beginning on November 4, 2011.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.